0.0600USD0.00%Mkt Cap: 7.84M USDP/E: —Last update: 2026-05-22
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. Th…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap7.84M USD
Enterprise Value46.02M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-23.55M USD
Revenue/Share—
Last Price0.0600 USD
Fiscal Year EndDec 2024
MR QuarterMar 2025
Employees26
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.02
EV/Revenue—
P/S—
P/B-0.06
EPS (TTM)-1.33
EPS (Forward)—
52W Range
0.001013% of range0.4600
52W High0.4600 USD
52W Low0.0010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-93.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.95M USD
CapEx (TTM)48.00K USD
FCF Margin—
FCF Yield-267.32%
Net Debt38.19M USD
Net Debt/EBITDA-1.68
Balance Sheet
Debt/Equity-0.34
Current Ratio0.05
Quick Ratio0.00
Book Value/Sh-0.9810 USD
Cash/Share0.0000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.130.60M
Float67.59M
Insiders58.97%
Institutions2.11%
Short Interest
Short Ratio0.4d
Short % Float5.53%
Short % Out.3.35%
Shares Short1.51M
Short (prev mo.)561.27K
Technical
SMA 500.0739 (-18.8%)
SMA 2000.0732 (-18.1%)
Beta0.65
S&P 52W Chg28.31%
Avg Vol (30d)3.30K
Avg Vol (10d)1.64K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—